Cargando…

Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program

INTRODUCTION: Ixekizumab, a highly selective interleukin-17A monoclonal antibody, was approved for the treatment of moderate-to-severe psoriasis (PsO) in 2016. Limited real-world data are available on its effectiveness from a patient’s perspective shortly (2 to 4 weeks) after initiation and upon con...

Descripción completa

Detalles Bibliográficos
Autores principales: Gottlieb, Alice B., Burge, Russel, Malatestinic, William N., Zhu, Baojin, Zhao, Yunyang, McCormack, Julie, Kimel, Miriam, Merola, Joseph F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366062/
https://www.ncbi.nlm.nih.gov/pubmed/37434099
http://dx.doi.org/10.1007/s13555-023-00969-1
_version_ 1785077090192719872
author Gottlieb, Alice B.
Burge, Russel
Malatestinic, William N.
Zhu, Baojin
Zhao, Yunyang
McCormack, Julie
Kimel, Miriam
Merola, Joseph F.
author_facet Gottlieb, Alice B.
Burge, Russel
Malatestinic, William N.
Zhu, Baojin
Zhao, Yunyang
McCormack, Julie
Kimel, Miriam
Merola, Joseph F.
author_sort Gottlieb, Alice B.
collection PubMed
description INTRODUCTION: Ixekizumab, a highly selective interleukin-17A monoclonal antibody, was approved for the treatment of moderate-to-severe psoriasis (PsO) in 2016. Limited real-world data are available on its effectiveness from a patient’s perspective shortly (2 to 4 weeks) after initiation and upon continuation for 24 weeks. OBJECTIVE: To describe patient-reported clinical and quality-of-life outcomes after initiating ixekizumab using data collected from the United States Taltz® Customer Support Program. METHODS: This was a 24-week prospective, observational study of commercially insured diagnosis-confirmed adults with PsO. Surveys were completed at weeks 0 (baseline), 2, 4, 8, 12, and 24 and included the Patient Report of Extent of Psoriasis Involvement questionnaire to assess the extent of body surface area (BSA) affected by PsO, itch and pain numeric rating scales, Patient Global Assessment of Disease Severity (PatGA), and Dermatology Life Quality Index (DLQI). RESULTS: 523 patients were included in the analysis. Proportions of patients with ≤ 2% BSA involvement were 34.5%, 40.1%, 50.9%, and 79.9% at weeks 0, 2, 4, and 24, respectively; 54.8% and 75.1% achieved National Psoriasis Foundation preferred (BSA ≤ 1%) and acceptable (BSA ≤ 3% or ≥ 75% improvement) responses at week 12, respectively. Improvements of ≥ 4 points in itch and pain were seen by week 2 in 21.1% and 28.0% of patients, respectively, which increased to 63.1% and 64.8% at week 24. Proportions of patients with PatGA scores of 0 (clear) or 1 were 13.4%, 24.1%, 34.0%, and 69.6% at weeks 0, 2, 4, and 24, respectively; and proportions with DLQI total scores of 0 or 1 [no or minimal impact] were 8.4%, 17.6%, 27.3%, and 53.8% at weeks 0, 2, 4, and 24, respectively. CONCLUSION: Patient-reported improvements in BSA, itch, skin pain, dermatology-specific quality of life, and overall PsO severity were seen as early as 2 weeks after initiation and continued through week 24. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13555-023-00969-1.
format Online
Article
Text
id pubmed-10366062
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-103660622023-07-26 Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program Gottlieb, Alice B. Burge, Russel Malatestinic, William N. Zhu, Baojin Zhao, Yunyang McCormack, Julie Kimel, Miriam Merola, Joseph F. Dermatol Ther (Heidelb) Original Research INTRODUCTION: Ixekizumab, a highly selective interleukin-17A monoclonal antibody, was approved for the treatment of moderate-to-severe psoriasis (PsO) in 2016. Limited real-world data are available on its effectiveness from a patient’s perspective shortly (2 to 4 weeks) after initiation and upon continuation for 24 weeks. OBJECTIVE: To describe patient-reported clinical and quality-of-life outcomes after initiating ixekizumab using data collected from the United States Taltz® Customer Support Program. METHODS: This was a 24-week prospective, observational study of commercially insured diagnosis-confirmed adults with PsO. Surveys were completed at weeks 0 (baseline), 2, 4, 8, 12, and 24 and included the Patient Report of Extent of Psoriasis Involvement questionnaire to assess the extent of body surface area (BSA) affected by PsO, itch and pain numeric rating scales, Patient Global Assessment of Disease Severity (PatGA), and Dermatology Life Quality Index (DLQI). RESULTS: 523 patients were included in the analysis. Proportions of patients with ≤ 2% BSA involvement were 34.5%, 40.1%, 50.9%, and 79.9% at weeks 0, 2, 4, and 24, respectively; 54.8% and 75.1% achieved National Psoriasis Foundation preferred (BSA ≤ 1%) and acceptable (BSA ≤ 3% or ≥ 75% improvement) responses at week 12, respectively. Improvements of ≥ 4 points in itch and pain were seen by week 2 in 21.1% and 28.0% of patients, respectively, which increased to 63.1% and 64.8% at week 24. Proportions of patients with PatGA scores of 0 (clear) or 1 were 13.4%, 24.1%, 34.0%, and 69.6% at weeks 0, 2, 4, and 24, respectively; and proportions with DLQI total scores of 0 or 1 [no or minimal impact] were 8.4%, 17.6%, 27.3%, and 53.8% at weeks 0, 2, 4, and 24, respectively. CONCLUSION: Patient-reported improvements in BSA, itch, skin pain, dermatology-specific quality of life, and overall PsO severity were seen as early as 2 weeks after initiation and continued through week 24. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13555-023-00969-1. Springer Healthcare 2023-07-11 /pmc/articles/PMC10366062/ /pubmed/37434099 http://dx.doi.org/10.1007/s13555-023-00969-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Gottlieb, Alice B.
Burge, Russel
Malatestinic, William N.
Zhu, Baojin
Zhao, Yunyang
McCormack, Julie
Kimel, Miriam
Merola, Joseph F.
Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program
title Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program
title_full Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program
title_fullStr Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program
title_full_unstemmed Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program
title_short Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program
title_sort ixekizumab real-world effectiveness at 24 weeks in patients with psoriasis: data from the united states taltz customer support program
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366062/
https://www.ncbi.nlm.nih.gov/pubmed/37434099
http://dx.doi.org/10.1007/s13555-023-00969-1
work_keys_str_mv AT gottliebaliceb ixekizumabrealworldeffectivenessat24weeksinpatientswithpsoriasisdatafromtheunitedstatestaltzcustomersupportprogram
AT burgerussel ixekizumabrealworldeffectivenessat24weeksinpatientswithpsoriasisdatafromtheunitedstatestaltzcustomersupportprogram
AT malatestinicwilliamn ixekizumabrealworldeffectivenessat24weeksinpatientswithpsoriasisdatafromtheunitedstatestaltzcustomersupportprogram
AT zhubaojin ixekizumabrealworldeffectivenessat24weeksinpatientswithpsoriasisdatafromtheunitedstatestaltzcustomersupportprogram
AT zhaoyunyang ixekizumabrealworldeffectivenessat24weeksinpatientswithpsoriasisdatafromtheunitedstatestaltzcustomersupportprogram
AT mccormackjulie ixekizumabrealworldeffectivenessat24weeksinpatientswithpsoriasisdatafromtheunitedstatestaltzcustomersupportprogram
AT kimelmiriam ixekizumabrealworldeffectivenessat24weeksinpatientswithpsoriasisdatafromtheunitedstatestaltzcustomersupportprogram
AT merolajosephf ixekizumabrealworldeffectivenessat24weeksinpatientswithpsoriasisdatafromtheunitedstatestaltzcustomersupportprogram